Literature DB >> 9224861

The effect of fixation condition manipulations on antisaccade performance in schizophrenia: studies of diagnostic specificity.

J E McDowell1, B A Clementz.   

Abstract

This series of studies evaluated (1) hypotheses that poor antisaccade performance is attributable to confounding variables (e.g., visual attention deficits, incomplete understanding of task demands) and (2) the specificity of poor antisaccade performance to schizophrenia. In addition to self-correcting errors before being cued to do so, schizophrenia patients also showed the expected saccadic reaction time changes to fixation condition manipulations: decreased latencies for gap and increased latencies for overlap trials. These data suggest that schizophrenia patients are adequately engaged in and understand the antisaccade task. Schizophrenia patients made fewer correct antisaccade responses than other psychiatric patients (obsessive-compulsive and bipolar disorder) and normal subjects. The first-degree relatives of schizophrenia patients also generated a decreased proportion of correct antisaccade responses compared with normal subjects. For schizophrenia patients who performed below the range of normal subjects, 26% of their relatives also performed below the normal range. Conversely, patients who performed normally did not have a single poor-performing relative. These data suggest that increased antisaccade error rates may index a liability for schizophrenia within a subset of families.

Entities:  

Mesh:

Year:  1997        PMID: 9224861     DOI: 10.1007/pl00005702

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  29 in total

1.  Smooth pursuit and saccadic eye movement performance in a prefrontal leukotomy patient.

Authors:  D C Gooding; W G Iacono; D R Hanson
Journal:  J Psychiatry Neurosci       Date:  1999-11       Impact factor: 6.186

2.  The antisaccade task and neuropsychological tests of prefrontal cortical integrity in schizophrenia: empirical findings and interpretative considerations.

Authors:  Deborah L Levy; Nancy R Mendell; Philip S Holzman
Journal:  World Psychiatry       Date:  2004-02       Impact factor: 49.548

3.  Impaired volitional saccade control: first evidence for a new candidate endophenotype in obsessive-compulsive disorder.

Authors:  Lisa Kloft; Benedikt Reuter; Anja Riesel; Norbert Kathmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-05-29       Impact factor: 5.270

4.  Pre-cue fronto-occipital alpha phase and distributed cortical oscillations predict failures of cognitive control.

Authors:  Jordan P Hamm; Kara A Dyckman; Jennifer E McDowell; Brett A Clementz
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

5.  Behavioral plasticity of antisaccade performance following daily practice.

Authors:  Kara A Dyckman; Jennifer E McDowell
Journal:  Exp Brain Res       Date:  2004-11-13       Impact factor: 1.972

6.  Common neural circuitry supporting volitional saccades and its disruption in schizophrenia patients and relatives.

Authors:  Jazmin Camchong; Kara A Dyckman; Benjamin P Austin; Brett A Clementz; Jennifer E McDowell
Journal:  Biol Psychiatry       Date:  2008-08-09       Impact factor: 13.382

7.  Does performance on the standard antisaccade task meet the co-familiality criterion for an endophenotype?

Authors:  Deborah L Levy; Elizabeth A Bowman; Larry Abel; Olga Krastoshevsky; Verena Krause; Nancy R Mendell
Journal:  Brain Cogn       Date:  2008-10-07       Impact factor: 2.310

Review 8.  Eye tracking dysfunction in schizophrenia: characterization and pathophysiology.

Authors:  Deborah L Levy; Anne B Sereno; Diane C Gooding; Gilllian A O'Driscoll
Journal:  Curr Top Behav Neurosci       Date:  2010

Review 9.  The tell-tale tasks: a review of saccadic research in psychiatric patient populations.

Authors:  Diane C Gooding; Michele A Basso
Journal:  Brain Cogn       Date:  2008-10-23       Impact factor: 2.310

10.  Preattentional and attentional cognitive deficits as targets for treating schizophrenia.

Authors:  David L Braff; Gregory A Light
Journal:  Psychopharmacology (Berl)       Date:  2004-04-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.